A National Consumers League Stakeholder Forum

Biologics:  The Pathway to Biosimilar Products?

September 18, 2007

AFL-CIO Building

Presidents Room, First Floor 

815 16th Street, NW

Washington, DC

 

Agenda

 

8:30 – Welcome – Linda Golodner, President, NCL (Moderator)

 

8:45 - 9:30 – Opening - Status of legislation

Ann Witt, Health Counsel, Office of Representative Henry Waxman (D-Ca)

Nick Shipley, Legislative Director, Office of Representative Jay Inslee (D-Wa)

  

9:30 - 10:00 - Panel 1 - Issues around developing a biosimilar biologics market

Roger Williams, Executive Vice President and Chief Executive Officer, United States Pharmacopeia (USP)

William Schultz, Partner, Zuckerman Spaeder LLP

Erika Lietzan, Partner, Covington & Burling LLP

 

10:00 - 10:45 – Discussion

 

10:45 - 11:00 – Break

 

11:00 - 11:40 - Panel 2 - Exploring the economic and practical implications of biosimilar biologics for health care payers, consumers, health care providers, and society 

David Borenstein, George Washington University Medical Center, American College of Rheumatology

Steven Miller, Chief Medical Officer, Express Scripts

Michael Brodeur, Head of Formulary Development & Pharmacy Clinical Policies, Aetna

Henry Grabowski, Professor of Economics, Duke University

Respondents: 

Shawn O’Neail, Associate Vice President, Federal Government Relations, National Multiple Sclerosis Society

Ruth Hoffman, National Executive Director, Candlelighters Childhood Cancer Foundation

 

11:40 - 12:30 – Discussion

 

12:30 - 1:30 – Lunch and speaker

Susan Dentzer, Health Correspondent, The NewsHour with Jim Lehrer